Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

Benzinga · 3d ago
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $66 to $64.